Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net income	$ 36,178,000	$ 49,791,000	$ 31,408,000
Adjustments to reconcile net income to net cash provided by operating activities:
Change in fair value of warrant liability	0	(2,649,000)	(9,571,000)
Depreciation and amortization	15,109,000	11,583,000	10,105,000
Amortization of deferred financing costs	169,000	946,000	3,126,000
Accretion of debt discount	55,000	3,710,000	5,295,000
Provision for doubtful accounts	570,000	512,000	661,000
Provision for inventory reserves and market adjustments	1,330,000	2,079,000	1,011,000
Gain on sale of assets	(4,565,000)	(4,819,000)	(3,378,000)
Impairment of goodwill, intangible assets or fixed assets	0	0
Stock compensation expense	10,914,000	13,421,000	7,437,000
Deferred income tax (benefit) provision	793,000	(18,746,000)	1,218,000
Excess in tax benefit related to share-based awards	(1,668,000)	(528,000)	(570,000)
Non-cash loss on extinguishment of debt	0	4,841,000	3,225,000
Changes in current assets and liabilities:
Restricted cash	150,000	0	0
Accounts receivable	(9,862,000)	1,796,000	(17,918,000)
Inventories	4,523,000	(9,368,000)	(11,054,000)
Other current assets	936,000	(2,073,000)	(892,000)
Accounts payable	(21,326,000)	2,527,000	5,041,000
Accrued liabilities	4,053,000	(1,894,000)	(255,000)
Income taxes payable	2,194,000	369,000	7,563,000
Interest payable	(5,000)	(1,983,000)	(29,000)
Net cash provided by operating activities	39,548,000	49,515,000	32,423,000
Cash flows from investing activities:
Capital expenditures	(15,007,000)	(20,701,000)	(9,984,000)
Proceeds from sale of assets	5,788,000	5,521,000	5,286,000
Payments for acquisition, net of cash acquired	(53,396,000)	0	0
Purchase of patents and other intangible assets	(85,000)	(20,000)	(244,000)
Net cash used in investing activities	(62,700,000)	(15,200,000)	(4,942,000)
Cash flows from financing activities:
Repayments of indebtedness	(13,206,000)	(102,438,000)	(33,273,000)
Proceeds from borrowings	26,190,000	25,000,000	0
Borrowings on revolving credit facility	313,396,000	0	0
Repayments on revolving credit facility	(297,124,000)	0	0
Debt issuance costs	(1,293,000)	(106,000)	(1,421,000)
Issuance costs of preferred stock and detachable warrants	(200,000)	0	0
Excess tax benefit related to share-based awards	1,668,000	528,000	570,000
Purchase of treasury stock	(7,568,000)	(2,034,000)	(775,000)
Proceeds from sale of common stock	824,000	161,000	29,438,000
Proceeds from exercise of stock options	491,000	167,000	147,000
Proceeds from Warrant Exercises	323,000	421,000	4,793,000
Net cash (used in) provided by financing activities	23,501,000	(78,301,000)	(521,000)
Effect of changes in exchange rates on cash and cash equivalents	(319,000)	4,000	(141,000)
Net increase (decrease) in cash and cash equivalents	30,000	(43,982,000)	26,819,000
Cash and cash equivalents at beginning of year	2,700,000	46,682,000	19,863,000
Cash and cash equivalents at end of year	$ 2,730,000	$ 2,700,000	$ 46,682,000